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Abstract: Glioblastoma is a highly aggressive primary brain tumour, renowned for its infiltrative
growth and varied genetic profiles. The current treatment options are insufficient, and their off-target
effects greatly reduce patient quality of life. The major challenge in improving glioblastoma diagnosis
and treatment involves the development of a targeted imaging and drug delivery platform, capable
of circumventing the blood brain barrier and specifically targeting glioblastoma tumours. The unique
properties of aptamers demonstrate their capability of bridging the gap to the development of
successful diagnosis and treatment options, where antibodies have previously failed. Aptamers
possess many characteristics that make them an ideal novel imaging and therapeutic agent for the
treatment of glioblastoma and other brain malignancies, and are likely to provide patients with a
better standard of care and improved quality of life. Their target sensitivity, selective nature, ease of
modification and low immunogenicity make them an ideal drug-delivery platform. This review article
summarises the aptamers previously generated against glioblastoma cells or its identified biomarkers,
and their potential application in diagnosis and therapeutic targeting of glioblastoma tumours.
Keywords: glioblastoma; aptamers; SELEX; cancer; targeted therapies; imaging; diagnosis;
biomarkers; blood brain barrier
1. Introduction
Glioblastoma or grade IV glioma is a highly malignant primary brain tumour with a particularly
poor median survival duration of 14 months [1]. Whilst the incidence rate of glioblastoma currently
stands markedly low at 3.2 per 100,000 population, its five-year survival rate is below 6% [2].
These tumours can arise spontaneously from glial cells, or can develop from the progression of
a lower grade glioma and are defined as primary or secondary glioblastomas, respectively (see
Figure 1) [3]. Histological features of glioblastoma include increased cellularity and angiogenesis,
vascular proliferation, hemorrhage, necrosis, and cystic regions throughout the tumours [4,5]. Cell
populations within these tumours tend to vary greatly, with the presence of both small, undifferentiated
cells and large cells with multiple nuclei reported [4].
According to the World Health Organization, glioblastomas are grouped into three categories
based on isocitrase dehydrogenase (IDH) status: glioblastoma IDH-wildtype, which is designated as
primary or to have originated de novo; glioblastoma IDH-mutant, which is identified as a secondary
tumour, arising from a lower grade glioma; and glioblastoma not otherwise specified (NOS) for
tumours when IDH evaluation cannot be performed [6]. An estimated 90% of glioblastoma arise de
novo, with the remaining 10% developing from a lower grade glioma [7]. Mutations of IDH lead
to hypermethylation of histones and DNA, altering gene expression, promoting the activation of
oncogenes and blocking tumour suppressing mechanisms [8]. A variety of genetic mutations are
implicated in glioblastoma development including the epidermal growth factor receptor (EGFR), human
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epidermal growth factor receptor two (ERBB2), isocitrase dehydrogenase one (IDH1), neurofibromin one (NF1),
phosphoinositide three-kinase (PI3K), phosphatase and tensin homolog (PTEN), retinoblastoma protein (RB1)
and tumour suppressor p53 (TP53) [9]. The gene expression patterns can be used to further categorise
glioblastomas into four sub-categories: proneural; neural; mesenchymal; and classical [10].
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brain tissue; however, they do overexpress EGFR [10,12].The current treatment modality includes 
surgery, radiotherapy, and chemotherapy with the DNA-alkylating agent temozolomide [1,13]. 
Surgery is performed to debulk the tumour thereby reducing mass effect symptoms in the patient, 
while also allowing for the collection of tissue specimens for histologic analysis [14]. Glioblastomas 
are renowned for their heterogeneity and infiltrative growth; complete surgical resection is near 
impossible as a result, and further complicated by the inability to differentiate the tumour from 
normal brain tissue [15]. Radiation and chemotherapy form the next line of treatment, aiming to 
destroy the cancer cells that were missed or could not be removed during surgery [1]. Temozolomide 
is a DNA-alkylating agent capable of inducing single- and double-stranded breaks in DNA, resulting 
in senescence and cell death [16]. Whilst surgery and the addition of temozolomide during and post-
radiotherapy has led to an increase in patient survival times, they are responsible for various adverse 
effects and poor quality of life in patients [13,17]. In addition, chemo-resistance and glioblastoma 
recurrence are inevitable for the majority of patients, highlighting the necessity of improved 
treatment options [16,18]. One of the greatest challenges facing modern medicine is the development 
of tumour targeting molecules, capable of specifically binding to their target with no adverse effects 
to normal cells and tissues within the body. Whilst the discovery and subsequent development of 
antibodies have become an integral part of scientific research, disease diagnosis and therapies, these 
molecules possess undesired characteristics and many pose significant risks to patients, limiting their 
clinical efficacy [19,20]. Antibody generation occurs in vivo, in both a time consuming and costly 
process, with incidences of great batch-to-batch variability [21]. The high cost of the complicated 
antibody production process limits their clinical use, particularly as large doses are needed for 
effective responses in patients [22]. Their large size hinders their ability to reach the desired targets 
due to poor tissue penetration, and can be irreversibly denatured by small changes in temperature, 
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The classical subtype is associated with amplification of chromosome 7 teamed with loss of
chromosome 10, EGFRoverexpression nd mutat ons. Mesenchym l glioblastomas maintain a
high expression of CH13L1, MET, and g nes associated with t mour necrosis factor a nuclear
factor-κB pathways, along with mutations and deletions of NF1. The proneural subclass parallels
secondary glioblastoma and lower-grade glioma with mutations in IDH1 and TP53, and modification
of platelet-derived growth factor receptor A (PDGFR-A) [10]. Finally, neural glioblastomas are similar
to normal brain tissue; however, they do overexpress EGFR [10,12].The current treatment modality
includes surgery, radiotherapy, and chemotherapy with the DNA-alkylating agent temozolomide [1,13].
Surgery is performed to debulk the tumour thereby reducing mass effect symptoms in the patient,
while also allowing for the collection of tissue specimens for histologic analysis [14]. Glioblasto as are
renowned for their het rogeneity nd infiltrative growth; c plete surgical resection is near mp ssible
as a result, and further complicated by the inability to differ ntiate the tumour fro nor al brain
tissue [15]. Radiation and chemotherapy form the next line of treatment, aiming to destroy the cancer
cells that were missed or could not be removed during surgery [1]. Temozolomide is a DNA-alkylating
agent capable of inducing single- and double-stranded breaks in DNA, resulting in senescence and cell
death [16]. Whilst surgery and the addition of temozolomide during and post-radiotherapy has led to
an increase in patient survival times, they are responsible for various adverse effects and poor quality
of life in patients [13,17]. In addition, chemo-resistance and glioblastoma recurrence are inevitable
for the majority of patients, highlighting the necessity of improved treatment options [16,18]. One of
the greatest challeng s facing modern medicine s th development of tumour targeting mol cules,
capable of specifically binding to th ir arget with no adverse effects t normal cells and tissues
within the body. Whilst the discovery and subsequent development of antibodies have become an
integral part of scientific research, disease diagnosis and therapies, these molecules possess undesired
characteristics and many pose significant risks to patients, limiting their clinical efficacy [19,20].
Antibody generation occurs in vivo, in both a time consuming and costly process, with incidences of
great batch-to-batch variability [21]. The high cost of the complicated antibody production process
limits their clinical use, particularly as large doses are needed for effective responses in patients [22].
Their large size hinders their ability to reach the desired targets due to poor tissue penetration, and can
be irreversibly denatured by small changes in temperature, thereby limiting their shelf life and transport
Int. J. Mol. Sci. 2017, 18, 2576 3 of 17
options [23]. Attempts have been made to humanize antibodies; however, complement-dependent
toxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and cytokine storms still occur in
patients [24–26]. Despite these known issues, antibodies remain in development and clinical trials,
while the development of alternatives with improved safety profiles are being investigated [27,28].
Targeted peptides and aptamers may bridge the gaps of diagnostic and therapeutic applications that
are currently unfilled by antibodies; however, targeted peptides have been reviewed extensively
elsewhere (see [29–31]) and fall beyond the scope of this review article. Targeted therapies will
pave the way for personalized cancer medicine, ensuring patients receive treatment based on their
tumour’s gene expression profiles, for effective treatment against glioblastoma and other currently
incurable conditions.
Further understanding of the altered and uncontrolled signaling pathways in glioblastoma has
potential to aid in the development of targeted treatments against the disease. Gene amplification
and overexpression of the EGFR protein and its mutant variant EGFRvIII contributes to glioblastoma
tumorigenesis and has been the target for new therapeutics [32,33]. Tyrosine kinase inhibitors of
EGFR block downstream signaling pathways by inhibiting ATP binding to the intracellular domain,
thereby impeding with responses leading to cell growth, invasion, and angiogenesis [34]. The use of
the EGFR tyrosine kinase inhibitors erlotinib and gefitinib have been evaluated in numerous clinical
trials, alone and in combination with standard glioblastoma treatment, with minimal effect on patient
survival [35–38]. Monoclonal antibodies have also been investigated for the treatment of glioblastoma.
In particular, bevacizumab was generated to inhibit vascular endothelial growth factor (VEGF) in order
to prevent angiogenesis, survival and migration of glioblastoma tumour cells [39]. Two large phase III
trials determined that the use of bevacizumab did not lead to increased survival compared to standard
treatment, despite this, it has remained in use to treat recurrent glioblastoma when temozolomide
rechallenge fails [40–42]. The unsuccessful development and clinical translation of more effective
treatments for glioblastoma are hindered by the restrictive nature of the blood brain barrier.
The blood brain barrier’s role is to control the passage of molecules and cells into the brain, in
order to protect this vital organ [43]. Tight junctions formed by a uniform monolayer of endothelial cells
maintain an almost impermeable barrier, increasing the difficulty of conveying chemotherapeutics into
the brain [44]. Great efforts have been made to develop mechanisms capable of delivering therapeutic
agents across this barrier, including both invasive and non-invasive strategies. The proposed invasive
strategies include temporary disruption of the blood brain barrier and intrathecal drug delivery [45–48].
A temporary disruption of the barrier can be achieved using focused ultrasound and its interaction
with microbubbles to alter the structure of the endothelial layer [49]. However, this technique can lead
to necrosis in the target tissue area, vasculitis, and seizures [50]. Intrathecal drug delivery introduces
therapeutics via direct injection into the cerebrospinal fluid [48]. While this is a simple method of
bypassing the blood brain barrier, the drugs are often filtered from the cerebrospinal fluid before they
reach the targeted area, and the use of a catheter often results in infection [47,51]. A less invasive
method involves chemically altering drugs, potentially by the addition of a lipid-like structure, or
modifying the drug to suit specific receptors, where it would be converted within the target organ to
the active state [52]. Modifying drugs may result in considerable changes from the parental drug, in
turn altering the pharmacodynamics and biological efficacy [44]. Finally, biological delivery systems
can be used to increase the uptake of drugs by transporters that would normally be used for essential
nutrients [53].
The presence of transport molecules on the surface of the blood brain barrier have recently
proven to be an effective mechanism to utilise for the delivery of substances into the brain via
receptor-mediated endocytosis. Yu and colleagues successfully utilised the transferrin receptor to
transport an antibody across the endothelial layer into the brain itself [54]. On the contrary, the use
of antibodies is associated with an immune response, therefore the development of a novel targeting
agent similar to antibodies is required for the safe treatment of brain malignancies [55]. The recent
development of a bi-functional aptamer capable of transcytosing across the blood brain barrier aided
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by the transferrin receptor in vivo, can be conjugated to a glioblastoma targeting aptamer (Figure 2),
and potentially improve its treatment modality [56].
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surface, and therefore lead to improved imaging signals and intratumoural delivery of therapeutic 
agents, comparative to antibodies [22,63]. Chemotherapeutic agents can be attached to aptamers in 
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Figure 2. The fusion of a transferrin aptamer with a glioblastoma targeting aptamer would create
a bi-functional aptamer capable of crossing the blood brain barrier to target glioblastoma tumour
tissues specifically. This targeted mechanism may be utilised for the safe delivery of both imaging and
therapeutic agents, sparing healthy cells throughout the body and the surrounding brain tissues from
off-target effects.
2. Aptamers
Aptamers, also referred to as ‘chemical antibodies’ are single stranded oligonucleotides capable
of binding to a target via shape recognition, in a similar fashion to antibodies [57]. Aptamers are
generated against specific targets via the process of the systematic evolution of ligands by exponential
enrichment (SELEX) and their sequence can be modified to optimise binding affinity and selectivity
(see Figure 3) [58–61]. The selection of aptamers occurs in vitro, as does their subsequent manufacture,
leading to little to no variation between batches, low immunogenicity, and are a considerably smaller
size than antibodies, further increasing their ease of tissue penetrati n [62]. The enhanced binding
properties of aptamers can saturate the available binding sites o the tumour surface, and therefore
lead to improved imaging signals and in ratumoural delivery of therapeutic agents, comparative to
antibodies [22,63]. Chemotherapeutic agents can be attached to aptamers in order to deliver them
to tumour cells, thereby reducing unwanted off-target effects, a particularly important factor for
the development of new therapeutic agents for brain tumours [57]. Specificity of aptamer binding
highlights their suitability for tumour imaging and targeted drug delivery, particularly in an organ as
important as the brain. The attachment of imaging agents to aptamers has previously been achieved,
and may lead to the development of more effective tumour imaging strategies for both histologic
analysis of tissues as well as determining tumour location within the patient [64–67]. The use of
aptamers for both imaging and therapeutic delivery have been reviewed extensively elsewhere [68–71].
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Figure 3. Sch matic repres ntation f a Cell-SELEX (s t atic evoluti n of ligands by exponential
enrichment) protocol. Initially, a single-stranded DNA library is incubated with the target cells. The
cells are washed to remove the unbound sequences, and the bound sequences are collected, prior to
incubation with negative (control) cells. The bound sequences are removed and discarded, whilst
the unbound sequences are amplified and used to begin the next round of SELEX. This cycle is
repeated a number of times, before the pool is sequenced and characterised. The bold arrows denote
one iterative round of SELEX, with the small arrows d picting the different steps of the protocol:
incubation of the single-stranded DNA library with the target cells; washing and removal of the
unbound sequences, incubation with negative cells; removal of bound sequences; collection of bound
sequences; amplification and cycle repetition prior to sequencing and aptamer characterization.
3. Glioblastoma Targeting Aptamers
To date, a multitude of aptamers have been generated against cell membrane proteins expressed
on glioblastoma cells (see Tables 1 and 2). These aptamers have potential to be used to identify new
biomarkers, and to specifically deliver imaging or therapeutic agents to revolutionise glioblastoma
diagnosis and treatment (see Figure 4).
Table 1. Glioblastoma aptamers and their SELEX m th ds.
Aptamer Target SELEX Method Positive Selection Negative Selection Reference(s)
A3, A4 Unknown Differentialcell-SELEX CD133+ TIC
CD133− cells; human
neural progenitor cells [72]
TTA1 Tenascin-C Crossover-SELEX U251 cells; humanTenascin-C No negative selection [66,73]
GBI-10 Tenascin-C Cell-SELEX U251 cells No negative selection [74,75]
Gint4.T PDGFRβ Cell-SELEX U87MG cells No negative selection [76,77]
GL21.T Axl Differentialcell-SELEX U87MG cells T98G ells [77–80]
U2 EGFRvIII Differentialcell-SELEX
U87MG-EGFRvIII
cells U87MG cells [81]
Aptamer 32 EGFRvIII Differentialcell-SELEX
U87MG-EGFRvIII
cells U87MG cells [82–84]
E07 EGFR;EGFRvIII Protein-SELEX Human EGFR No negative selection [85–87]
GMT 3–9 Unknown Differentialcell-SELEX A172 cells No negative selection [88]
GBM128, GBM131 Unknown Differentialcell-SELEX U118-MG cells SVGp12 cells [89]
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Table 2. Aptamers generated against potential biomarkers for glioblastoma targeting.
Aptamer Target SELEX Method Positive Selection NegativeSelection Reference(s)
CD133-A15, CD133-B19 CD133 Differential cell-SELEX HEK293T-CD133 cells HEK293T cells [90]
CL4 EGFR; EGFRvIII Differential cell-SELEX A549 cells H460 cells [91–93]
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Figure 4. Schematic representation of aptamers for targeting glioblastoma tissue. (A) Targeted delivery
of imaging agents to glioblastomas with the use of a bi-functional aptamer conjugated with an imaging
agent such as radionuclides, may improve tumour detection; (B) Therapeutic agents can be conjugated
to the bi-functional aptamer for the specific delivery to the glioblastoma cells, thereby reducing
unwanted off-target effects and sparing the healthy surrounding tissues and throughout the rest of
the body.
3.1. Aptamers Targeting Tumour Intitiating Cells
A relatively new concept in cancer biology is the discovery of tumour initiating cells (TIC),
referred to as cancer stem cells, thought to be a driving force in tumour development and therapeutic
resistance [94]. While a population of TIC in glioblastomas can be identified by the glycoprotein
CD133, some CD133-negative cells in these tumours have the ability to self-renew, thus this marker
may not be indicative of all stem cells within glioblastoma tumours [95]. It should be noted that the
CD133 receptor, usually detected with the AC133 epitope monoclonal antibody, can become truncated,
thereby hindering the antibody’s acc s to its binding regi n and leading to false-negative CD133
expression results in cancer cell populations [96]. As such, CD133 expression ho ld be confirmed
with multiple techniques. Despite these controversies, CD133 is still an attractive therapeutic target
that requires further investigation due to its presence within these tumours.
To develop aptamers against CD133, Shigdar et al. utilised differential cell-SELEX with
HEK293T-CD133 transfected cells and normal HEK293T cells as a negative control, to ensure the
aptamers were binding to the desired epitope [90]. The generation of RNA containing 2′-F-pyrimidine
aptamers capable of binding to CD133 was confirmed using both CD133 positive, and negative cell
lines, via flow cytometry and confocal microsco y. The CD133-A15 aptamer binds to the AC133 epitope,
similar to that of he standard antibody used for this rec ptor’s detection. In contr st, CD133-B19 does
not bind to the AC133 epitope and ther fore has p tential to be used to detect cancer stem cells within
glioblastoma tumours, as well as potentially deliver therapeutics to these target cells.
Differential cell-SELEX was also utilised to generate the aptamers A3 and A4 against glioblastoma
TIC, by using cells extracted from human glioblastoma tissue xenografts [72]. The collected cells
were sorted based on CD133 expression and used for positive and negative selection in all SELEX
rounds, with the addition of human neural progenitor cells as an extra counter selection step to
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promote binding to a cancer surface marker. This selection process developed aptamers capable of
specific binding and uptake to glioblastoma TIC, generating a potential method for their detection and
treatment. Further characterisation of the identified aptamers is required to determine their molecular
targets and determine their efficacy as diagnostic or therapeutic delivery agents.
3.2. Aptamers Targeting Tenascin-C
Tenascin-C is a large glycoprotein found in the extracellular matrix [73]. While normal adult
tissues have little or no expression, higher levels are present during foetal development, wound
healing, atherosclerosis, psoriasis, and tumour growth [97,98]. The high levels of tenascin-C expression
in tumours is associated with angiogenesis, and may be an effective biomarker for diagnosis and
treatment [73].
The aptamer TTA1 was developed via a crossover-SELEX protocol with U251 glioblastoma cells
and purified human tenascin-C [73]. This aptamer was generated with RNA containing 2′-F-pyrimidine
to induce resistance to nucleases in the blood, and was truncated prior to further modifications to
improve aptamer stability and half-life with the substitution of 2′-OCH3 purines, the addition of a
thymidine cap at the 3′ end, and a 5′ amine as a conjugation site. In vitro testing determined the
aptamer to bind to human tenascin-C with high affinity, with a 20-fold reduction in affinity to the
mouse protein. The addition of the conjugate site on TTA1 enables the attachment of various molecules,
ensuring its adaptability for various clinical applications. 99mTc radiolabelled-TTA1 administered
intravenously to nude mice successfully targeted tumour xenografts of U251 glioblastoma cells and
MDA-MB-435 breast cancer cells, and its rapid clearance from the blood and uptake into the tumours
indicates TTA1 as a viable tumour imaging modality [66]. It should be noted that there are limitations
with the use of animals as human disease models, as xenografts do not wholly replicate the disease that
occurs in humans [99]. The use of cultured cells in xenografts can lead to tumours with genetic profiles
differing greatly from patient tumours and therefore do not always accurately represent treatment
outcomes in patients. The use of xenograft models for glioblastoma tumours completely fails to
replicate the cancer’s microenvironment, and indeed the ability of these aptamers to cross the blood
brain barrier, as these xenografts are heterotopic. Despite these drawbacks, animal models still provide
important information for translational drug development prior to experimental clinical trials, and
give great insight into efficacy of newly developed imaging agents. It is vital that the TTA1 aptamer is
tested in healthy animal models to determine if it is capable of specifically targeting tumour tissue and
also asses its ability to cross the blood brain barrier. If TTA1 is not able to do so, this aptamer may be
attached to a transferrin aptamer to ensure its successful transition into the brain. TTA1 must also be
tested in animal models that provide a relevant clinical representation of glioblastoma, to ensure its
effectiveness as both a diagnostic and therapeutic delivery agent.
Another aptamer capable of specifically binding to tenascin-C is GBI-10, a DNA aptamer generated
against U251 glioblastoma cells. Radiolabeling GBI-10 with positron emission tomography (PET)
isotopes, 18F and 64Cu, developed aptamers capable of imaging tenascin-C within U87MG glioblastoma
and MDA-MB-435 breast cancer xenografts in mice [74]. The aptamer’s rapid clearance hindered
intratumoural uptake; although these properties are ideal for PET imaging agents, they would need to
be modified for effective therapeutic delivery in in vivo systems. To improve GBI-10’s stability and
affinity, D-/L-isonucleotides and 2′-dI phosphoramidite were incorporated into the aptamer structure,
and successfully increased the binding affinity to U251 cells in vitro [75]. Aptamer binding affinity
and serum stability are vital characteristics that determine their efficacy as diagnostic or drug-delivery
platforms. Modifications to aptamers to improve their half-life and targeting ability may be vital
to ensure their success in clinical applications. Further testing is warranted in more appropriate
glioblastoma animal models to prove GBI-10’s capability to specifically target glioblastoma tissues in a
clinically relevant in vivo system.
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3.3. Aptamers Targeting Platelet Derived Growth Factor Receptor β
Overexpression and mutations of the platelet derived growth factor receptor (PDGFR) are
associated with gliomagenesis and tumour progression [100]. In glioblastoma, deregulation of the
PDGFR signaling cascade and overexpression of this receptor is frequently displayed, indicating it as a
potential therapeutic target [101].
Cell-SELEX was employed to develop a 2′-F-pyrimidine containing RNA aptamer capable of
recognising platelet derived growth factor receptor β (PDGFRβ) [76]. This aptamer, Gint4.T, was
determined to internalise into the U87MG glioblastoma cells, indicating its ability to be developed
as a targeted delivery platform of therapeutics to the tumour tissues. Binding of this aptamer to the
PDGFRβ was found to interfere with the receptor’s signaling cascade by preventing phosphorylation
of the tyrosine kinase domains, thereby reducing cell proliferation and migration both in vitro
and in athymic CD-1 nude mice tumour xenografts in vivo. To prove Gint4.T’s success as a
therapeutic delivery platform, this aptamer was conjugated with anti-microRNA-10b to counteract
expression of the oncogenic microRNA-10b seen in glioblastoma cancer stem cells, and induced
cellular differentiation, thereby preventing tumoursphere growth and development when combined
with GL21.T conjugated with microRNA-37 [77]. Interestingly, Gint4.T was capable of crossing the
blood brain barrier in a physiologically relevant in vitro model previously developed by Kumar and
associates (see [102]), likely via receptor mediated transcytosis, although this is yet to be replicated in
an in vivo model. The ability of this aptamer to cross the blood brain barrier and specifically target
glioblastoma cancer stem cells may lead to an effective therapeutic against this normally evasive cell
population, thereby improving prognosis and increasing survival times for glioblastoma patients.
3.4. Aptamers Targeting Axl
Axl is a receptor tyrosine kinase commonly overexpressed in glioblastomas and other
systemic tumours, associated with cancer cell survival, angiogenesis, proliferation, invasion, and
motility [103–105]. The GL21.T aptamer is capable of binding and inhibiting Axl signaling, and may
serve as a novel therapeutic agent to control tumour cell growth and invasion driven by this oncogenic
protein [78]. This aptamer reduced migration and invasion of A549 lung cancer cells and U87MG
glioblastoma cells in vitro and in athymic CD-1 nude mice xenografts in vivo. As previously mentioned,
GL21.T conjugated with microRNA-37 used in combination with microRNA-10b-conjugated Gint4.T,
transformed tumourspheres into adherent-like cells, inhibiting their ability to grow in spheroid
form [77]. GL21.T was also able to traverse the in vitro blood brain barrier model, if this aptamer is
capable of crossing this barrier in vivo, it could potentially be developed as a therapeutic targeting
agent in the clinical setting. However, previous attempts to inhibit PDGFR in clinical trials have failed
due to tumour resistance and pathway compensatory mechanisms [79,80]. Therefore, GL21.T should
be used as a therapeutic delivery platform, and used in combination with other targeted therapies to
ensure complete tumour eradication.
3.5. Aptamers Targeting the Epidermal Growth Factor Receptor
EGFR is involved with important cellular functions including cell growth, differentiation,
survival, and migration, and deregulation of its signaling cascade is a driving force of glioblastoma
tumorigenesis [32,106]. An aptamer capable of targeting EGFR and the mutant variant EGFRvIII
would serve to be an ideal candidate for use in glioblastoma therapy, as their overexpression and
mutation are prevalent in the majority of glioblastoma tumours [32].
An anti-EGFR RNA aptamer, CL4, capable of binding to both the wildtype and mutant variant has
previously been generated via differential cell-SELEX with lung cancer cell lines [91]. Upon binding to
the target receptor, CL4 prevented tyrosine-phosphorylation in a time-dependent manner, decreasing
cell viability, proliferation, migration, and invasion in vitro [91,92]. Whilst minimal in vivo work has
been undertaken with CL4, promising results from a triple-negative breast cancer xenograft model
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in athymic CD-1 nude mice determined this aptamer was capable of reducing tumour size, without
inducing toxicity in the treated mice [93]. CL4 displays a therapeutic effect against EGFR activation;
however, EGFR inhibitors have failed to prove success as monotherapies for glioblastoma, as such,
CL4 should be used as a shuttle for therapeutic or diagnostic agents to these tumours in order to have
clinical success [107].
Differential cell-SELEX developed an aptamer, U2, with U87MG cells expressing EGFRvIII or
wildtype EGFR as positive and negative selectors, respectively [81]. This aptamer’s high affinity for the
membrane receptors indicated its potential use as a diagnostic agent. Therefore, U2 was radiolabelled
with 188Re to investigate its ability to function as a molecular probe in EGFRvIII expressing glioblastoma
xenografts in male BALB/c nude mice. This aptamer successfully accumulated in the target tumours,
highlighting its potential to be used as an effective glioblastoma imaging tool. There is little evidence
to date that suggests U2 can penetrate the blood brain barrier in these mice, as such, conjugation
with a transferrin receptor aptamer would ensure effective transport into the brain, though this
would need to be extensively investigated both in vitro and in vivo. Tan et al. created aptamer
32 via differential cell-SELEX, utilising U87MG-EGFRvIII cells as the target for aptamer selection
and U87MG cells as a negative control [82]. Binding assays were performed to evaluate aptamer
specificity, with aptamer 32 showing binding to the U87MG-EGFRvIII target cells, and no binding to
U87MG cells or the kidney cell line HEK293. Pull-down assays and confocal microscopy concluded
the aptamer’s target was EGFRvIII, and the aptamer was translocated to the nucleus of target cells,
indicating its potential to be used for the targeted delivery of therapeutics within glioblastoma tumours.
A follow-on study conjugated c-Met small interfering RNA (siRNA) to aptamer 32, and successfully
delivered the siRNA to target U87MG-EGFRvIII cells, inhibiting the target gene’s expression and
cell proliferation whilst inducing apoptosis [83]. Conjugation of aptamer 32 to quantum dots could
verify the expression of EGFRvIII in various glioblastoma tissues, the presence of this receptor was
confirmed with immunohistochemistry [84]. This novel imaging probe was also capable of crossing
the blood brain barrier in vivo, and accumulated in tumour tissues within the brains of male nude
mice. Analysis of mouse body weight and major organs determined that the quantum dot-aptamer
conjugates did not induce toxicity in the animals, further highlighting this aptamer’s potential for use
in the clinical setting. Overall, these results indicate aptamer 32 as a candidate tumour imaging probe
and as a therapeutic delivery platform for the treatment of glioblastoma, though further investigation
is required to determine aptamer 32’s mechanism of crossing the blood brain barrier, and to further
determine its stability and specificity to glioblastoma tumours within the brain.
An alternative SELEX method was employed to develop a 2′-F-pyrimidine containing RNA
aptamer against human EGFR protein [85]. This aptamer, E07, was determined to competitively
bind to both the wildtype and mutant variant three of EGFR, hindering ligand binding and
autophosphorylation of these receptors in vitro. E07 has since been utilised to successfully capture and
isolate circulating tumour cells with the use of biochips in vitro, with potential to be used for cancer
diagnosis and evaluation of metastasis in patients [86,87].
3.6. Targeting Nucleolin with a Guanine-Rich Oligonucleotide
Nucleolin is associated with ribosome biogenesis, and the overexpression of this protein in cancer
cells is linked to cell division, angiogenesis and inhibiting apoptosis, and therefore, is a viable target for
delivery of therapeutic agents to glioblastomas, or other forms of cancer [108,109]. The development
and use of guanine-rich oligonucleotides (GRO) stems from their intriguing biological properties,
notably, their enhanced uptake that could aid in the delivery of therapeutic agents to target tissues,
although they are known to display non-specific effects [110,111]. AS1411 is a GRO, utilised for its
antiproliferative effects and nucleolin targeting ability in vitro [112]. The efficacy of AS1411 as a cancer
therapy was replicated in vivo, as intraperitoneal injections were able to significantly reduce pancreatic
cancer xenograft growth in mice. In terms of using AS1411 as a treatment for glioblastoma, Luo et al.
successfully delivered AS1411-conjugated paclitaxel nanoconjugates to U87MG-PMT48 orthotopic
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glioblastoma xenografts in BALB/c nude mice, significantly increasing the median survival time for
the treated mice [113]. Despite these promising results, the clinical translation of AS1411 was not so
successful, with evaluation as a therapeutic in a phase II trial for metastatic renal cell carcinoma, only
one patient out of 35 responded to the treatment [114]. Rigorous evaluation of AS1411 as a glioblastoma
treatment in physiologically relevant in vitro and in vivo models is vital to ensure successful transition
into clinical trials, and the potential off-target uptake must be evaluated if AS1411 is to be used for
targeted drug delivery in the future.
3.7. Glioblastoma Aptamers with Unknown Targets
Cell-SELEX can be advantageous for aptamer development as whole cells have a myriad of surface
markers that aptamers could bind to, many which remain unidentified. Therefore, aptamers can be
generated against unknown surface markers that can later be identified, improving our knowledge of
glioblastoma and other cancers.
Cell-SELEX was employed to develop DNA aptamers using the A172 glioblastoma cell line [88].
The sequenced aptamers GMT 3, GMT 4, GMT 5, GMT 8, and GMT 9 bound to glioblastoma cells with
high affinity, and were further characterised to determine if binding was specific to glioblastoma cell
lines. GMT 4 and 8 bound to the CEM leukemia cells and breast cancer cells GMBJ1, indicating that
these cells share a surface marker recognised by these aptamers. Whilst these aptamers did bind to
the glioblastoma cells, they had increased affinities to one of each leukemic and breast cancer cell line
by more than two-fold. As such, these aptamers may have potential for use as a targeted imaging or
therapeutic delivery strategy in these cancers as well. Treatment with proteinase K and trypsin was
performed to determine if the aptamer binding targets were membrane proteins. All aptamers lost
binding affinity after proteinase K treatment, indicating all of the aptamers likely bind to proteins.
Trypsin application lead to a slight decrease in GMT 3 and 5 binding, demonstrating their targets
are resistant to trypsin cleavage. These results show that negative selection is vital to cell-SELEX to
identify aptamers specific to a tumour type, and to date, no publications have indicated the targets of
these aptamers.
Differential cell-SELEX generated aptamers GBM128 and 131 using U118-MG cells for positive
selection and astroglial cells SVGp12 for negative selection [89]. These aptamers were found to bind
to the U118-MG glioblastoma cells in vitro, and did not recognise the astroglial cell line used in the
SELEX process. Further testing with paraffin embedded tissues determined these aptamer’s ability to
bind to glioblastoma and glioma tissues, with no binding observed in the astroglial tissues. Whilst
these aptamers could not differentiate between glioblastoma and other glioma tumours, they did not
bind to normal brain tissue, indicating their potential use in glioma diagnosis. Further investigation is
required to determine the aptamers’ targets and prove their efficacy for glioma diagnosis.
3.8. Circumventing the Blood Brain Barrier
Whilst there are a number of aptamers that have been generated against cancer cells or their
surface markers, the majority have only been investigated in vitro. Although the results show good
selectivity, specificity, and efficacy, the challenge will be to see if these aptamers can cross the blood
brain barrier in clinical models. One way of rescuing these aptamers, should they fail, is to use a
transferrin receptor aptamer for receptor-mediated transcytosis in order to give these aptamers access
to the brain. This mechanism has been successfully utilised by Macdonald et al. with a bi-functional
aptamer capable of transcytosing through an in vitro blood brain barrier model, and also confirmed
to reach the brain of a healthy mouse model following intravenous injection [56]. The conjugation of
aptamers seen in the previous paper serves as a proof of concept that combining a cancer-targeting
aptamer to a transferrin receptor aptamer, can develop a bi-functional aptamer capable of transcytosing
through the blood brain barrier, to specifically target tumours within the brain.
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4. Conclusions
Brain cancers, particularly glioblastomas, have very poor five-year survival rates and there is
an urgent need to develop new therapeutic strategies with superior mechanisms of action to the
current available therapies. The issue of getting new therapies across the blood brain barrier has been
investigated in a number of studies, and there are now several strategies available to actively transport
therapeutics through the barrier in order to reach the cancer cells within the brain. Whilst some of
these transport mechanisms are unlikely to provide the patient with a better standard of care and
improved quality of life, there are some with potential to revolutionise the treatment of glioblastoma,
and other brain disorders.
Aptamers possess many characteristics that make them an ideal novel therapeutic agent for the
treatment of glioblastoma and other brain malignancies. Their target sensitivity, selective nature, ease of
modification and low immunogenicity make them an ideal drug-delivery platform. The development
and optimisation of aptamers capable of transcytosing through the blood brain barrier to specifically
deliver imaging and chemotherapeutic agents to glioblastoma tissues have potential to revolutionise
brain tumour treatment.
In conclusion, aptamers show great promise as novel agents for tumour detection and treatment,
although ongoing investigations are required to ensure their effective clinical translation. The research
performed to date indicates aptamers are an innovative diagnostic and therapeutic platform for
glioblastomas. Furthermore, these novel nucleic acids are improving our understanding of cancer and
glioblastoma biology.
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Abbreviations
ADCC Antibody-dependent cellular cytotoxicity
ATP Adenosine triphosphate
CDC Complement-dependent cytotoxicity
DNA Deoxyribose nucleic acid
EGFR Epidermal growth factor receptor
EGFRvIII Epidermal growth factor receptor variant three
ERBB2 Human epidermal growth factor receptor two
NF1 Neurofibromin one
NOS Not otherwise specified
PDGFRA Platelet derived growth factor receptor A
PDGFRβ Platelet derived growth factor receptor β
PI3K Phosphoinositide three-kinase
PTEN Phosphatase and tensin homolog
SELEX Systematic evolution of ligands by exponential enrichment
PET Positron emission tomography
RB1 Retinoblastoma protein
RNA Ribonucleic acid
siRNA Small interfering RNA
TIC Tumour initiating cells
TP53 Tumour suppressor p53
VEGF Vascular endothelial growth factor
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